Patents by Inventor Steve Ruben
Steve Ruben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11802164Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: January 21, 2020Date of Patent: October 31, 2023Assignee: Celera CorporationInventors: Steve Ruben, Tao He, Candy Lee, Karen Van Orden, Paul Moore
-
Publication number: 20210292407Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 19, 2021Publication date: September 23, 2021Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Publication number: 20210277073Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: January 7, 2021Publication date: September 9, 2021Inventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Patent number: 11105806Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: GrantFiled: June 28, 2019Date of Patent: August 31, 2021Assignee: Celera CorporationInventors: Charles Birse, Steve Ruben, Marcia Lewis, Mehdi Mesri
-
Publication number: 20210017259Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: March 25, 2020Publication date: January 21, 2021Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20200291129Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 21, 2020Publication date: September 17, 2020Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20200276329Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: January 8, 2020Publication date: September 3, 2020Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20200064347Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: ApplicationFiled: June 28, 2019Publication date: February 27, 2020Inventors: Charles BIRSE, Steve RUBEN, Marcia LEWIS, Mehdi MESRI
-
Publication number: 20190233484Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: December 5, 2018Publication date: August 1, 2019Inventors: Elizabeth Joseloff, Steve Ruben, Tao He
-
Patent number: 10338075Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: GrantFiled: November 8, 2016Date of Patent: July 2, 2019Assignee: Celera CorporationInventors: Charles Birse, Steve Ruben, Marcia Lewis, Mehdi Mesri
-
Publication number: 20180265591Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: January 10, 2018Publication date: September 20, 2018Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Publication number: 20180155421Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: October 18, 2017Publication date: June 7, 2018Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Publication number: 20170355752Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: April 24, 2017Publication date: December 14, 2017Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20170350897Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: April 12, 2017Publication date: December 7, 2017Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20170153238Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.Type: ApplicationFiled: November 8, 2016Publication date: June 1, 2017Inventors: Charles BIRSE, Steve RUBEN, Marcia LEWIS, Mehdi MESRI
-
Patent number: 9658232Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: GrantFiled: June 19, 2015Date of Patent: May 23, 2017Assignee: Celera CorporationInventors: Steve Ruben, Bruno Domon, Candy Lee
-
Publication number: 20160362461Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: April 19, 2016Publication date: December 15, 2016Inventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Publication number: 20160340425Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: December 7, 2015Publication date: November 24, 2016Inventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Publication number: 20160161494Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: June 19, 2015Publication date: June 9, 2016Inventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20150361181Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 24, 2015Publication date: December 17, 2015Inventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE